Showing results (101-110 of 136) with videos related to

Sort By:
Pageof 14
Blood|June 23, 2022
Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphomaSimone Ferrero, Daniele Grimaldi, Elisa Genuardi, et al.
Blood|February 26, 2005
Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcomeMarco Ladetto, Sonia Vallet, Andreas Trojan, et al.
Hemasphere|April 21, 2020
Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL NetworkDaniela Drandi, Marion Alcantara, Ichrafe Benmaad, et al.
Genes, Chromosomes & Cancer|May 13, 2011
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemiaMichele Dal Bo, Francesca Maria Rossi, Davide Rossi, et al.
Leukemia & Lymphoma|April 5, 2018
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana LinfomiFrancesco Zaja, Flavia Salvi, Maura Rossi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndromeDavide Rossi, Valeria Spina, Michaela Cerri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trialSara Galimberti, Stefano Luminari, Elena Ciabatti, et al.
Blood Advances|April 14, 2023
Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trialSimone Ferrero, Daniele Grimaldi, Elena Arrigoni, et al.
Hemasphere|May 4, 2026
Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)-MCL0208 clinical trialFrancesca Cordero, Simone Ferrero, Simone Pernice, et al.
Blood Cancer Discovery|July 2, 2024
A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell LymphomasFederico Stella, Annalisa Chiappella, Beatrice Casadei, et al.
Pageof 14